-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Promising Results for Lurbinectedin in SCLC When Paired with Irinotecan
Combined treatment with lurbinectedin and irinotecan appears to pack quite a punch in patients with relapsed small cell lung cancer (SCLC) according to the results of a phase Ib/II trial (Abstract OA11.04). The overall response rate (ORR) among 21 patients who had received up to 2 prior lines of treatment reached 62% overall, with a…
-
Deeper Understanding of EGFR Mutation Subgroups Will Further Personalize Treatment for NSCLC
New insights into the types of EGFR mutations that can arise in NSCLC may help guide decisions about the most appropriate targeted drugs for individual patients. A study by Jacqulyne Robichaux, PhD, of MD Anderson Cancer Center and colleagues (MA13.07) that used patient data, cell lines, and computerized models to analyze EGFR mutations found that the…
-
Trastuzumab Deruxtecan Potential New Treatment Options for HER2+ NSCLC
The novel antibody drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated clinically meaningful and promising efficacy in patients with HER2-mutated NSCLC, according to interim results of the DESTINY-Lung01 trial, presented as part of the mini oral session, “MA11: Expanding Targetable Genetic Alerations in NSCLC.” “These data demonstrate the potential of T-DXd as a new treatment option in…
-
New Nodal Descriptor Classification Potentially Better at Differentiating Patients
The IASLC’s proposed new classification of N descriptor is potentially better at differentiating patients with lung cancer into different stages, according to the results of a study presented during the mini oral session, “MA09: Prognosis and Staging,” held on Sunday. According to a presentation by Dariusz Dziedzic, MD, National Research Institute of Chest Diseases, Warsaw, Poland,…
-
Targeting KRAS in Lung Cancer: The Past, Present, and Future
Although RAS mutations constitute some of the most common genetic alterations in patients with adenocarcinomas, efforts to target the RAS oncoprotein have not proven fruitful, not only in NSCLC but across all cancers. In fact, researchers have been searching for an effective RAS inhibitor for more than 3 decades, leading many to believe that RAS…
-
Envisioning A Tobacco-Free Generation
Million-dollar ad campaign characters such as the Marlboro Man and Joe Camel lured many people to take up the tobacco habit through magazine ads and TV commercials. Gimmicks such as “Camel Cash” that could be mailed in, in exchange for prizes such as cigarette lighters and t-shirts, made tobacco users walking advertisements, perpetuating an ethos…
-
Nivolumab Boosted Survival in Relapsed Mesothelioma
Nivolumab significantly improved investigator-reported progression-free survival and overall survival compared with placebo in patients with relapsed malignant mesothelioma, according to preliminary results of the CONFIRM phase III trial presented during the Presidential Symposium. “Nivolumab is a safe and effective treatment and should be considered a new treatment option for patients with relapsed mesothelioma,” said Dean…
-
Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC
The first-in-class KRAS G12C inhibitor sotorasib has demonstrated early, deep, and durable responses in the treatment of advanced NSCLC with KRAS G12C mutations, according to results from the registrational phase II CodeBreaK 100 trial. “Breakthrough therapy designation was granted by U.S. Food and Drug Administration (FDA), and I am pleased to report that regulatory filings…
-
KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC
Patients with metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50% face greater toxicity without the benefit of enhanced efficacy when ipilimumab is combined with pembrolizumab in the first-line setting, according to findings of the phase III KEYNOTE-598 trial. In fact, the results at the first interim analysis for the immunotherapy combination were…
-
LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC
Primary results of the phase II Lung Cancer Mutation Consortium (LCMC) 3 clinical trial suggest that neoadjuvant atezolizumab may be a worthwhile treatment option for selected patients with resectable stage IB-IIIB NSCLC (Abstract PS01.05). Not only did 21% of patients lacking EGFR or ALK genetic aberrations attain a major pathologic response (MPR) at the time…
View ILCN Archives
Provider Resources
Popular Articles